Last reviewed · How we verify
Protein Phosphatase 2A Inhibitor LB-100
At a glance
| Generic name | Protein Phosphatase 2A Inhibitor LB-100 |
|---|---|
| Also known as | LB-100, PP2A Inhibitor LB-100 |
| Sponsor | City of Hope Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 (PHASE1, PHASE2)
- LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer (PHASE1)
- Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (PHASE1, PHASE2)
- LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer Patients (PHASE1)
- Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma (PHASE2)
- A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) (PHASE1, PHASE2)
- Phase I Study of LB-100 With Docetaxel in Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: